Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension

Circulation

Volumn 107, Issue 9, 2003, Pages 1329-1335

  Rondelet, Benoît ^a   Kerbaul, François ^a   Motte, Sophie ^a   Van Beneden, Ronald ^b   Remmelink, Myriam ^c   Brimioulle, Serge ^a   McEntee, Kathleen ^a   Wauthy, Pierre ^a   Salmon, Isabelle ^c   Ketelslegers, Jean Marie ^b   Naeije, Robert ^a  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c ERASME HOSPITAL   (Belgium)

Author keywords

Endothelin; Growth substances; Hypertension, pulmonary; Nitric oxide

Indexed keywords

BOSENTAN; ENDOTHELIN 1; ENDOTHELIN B RECEPTOR; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TENASCIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; ARTERY ANASTOMOSIS; ARTICLE; BLOOD VESSEL WALL; CONTROLLED STUDY; HEART RIGHT VENTRICLE; HEART VENTRICLE COMPLIANCE; IMMUNOHISTOCHEMISTRY; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG CIRCULATION; LUNG HEMODYNAMICS; LUNG PARENCHYMA; MORPHOMETRICS; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; QUANTITATIVE ASSAY; RANDOMIZATION; SHUNTING; SWINE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TUNICA MEDIA;

EID: 0037432296     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000053443.27512.33     Document Type: Article

References (34)

1. Archer S, Rich S. Primary pulmonary hypertension: a vascular biology and translational research "work in progress." Circulation. 2000;102: 2781-2791.
2. Eddahibi S, Adnot S. Endothelins and pulmonary hypertension: what directions for the near future? Eur Respir J. 2002;18:1-4.
3. Cacoub P, Dorent R, Maistre G, et al. Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. Am J Cardiol. 1993;71: 448-450.
4. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732-1739.
5. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
6. Rich S, ed. Primary Pulmonary Hypertension: Executive Summary from the World Symposium Primary Pulmonary Hypertension 1998. Geneva, Switzerland: World Health Organization. Available at: http://www. who.int/ncd/pph.html.
7. Rendas A, Lennox S, Reid L. Aorta-pulmonary shunts in growing pigs: functional and structural assessment of the changes in the pulmonary circulation. J Thorac Cardiovasc Surg. 1979;77:109-118.
8. De Canniere D, Stefanidis C, Brimioulle S, et al. Effects of a chronic aortopulmonary shunt on pulmonary hemodynamics in piglets. J Appl Physiol. 1994;77:1591-1596.
9. Hoffman JI, Rudolph AM, Heymann MA. Pulmonary vascular disease with congenital heart lesions: pathologic features and causes. Circulation. 1981;64:873-877.
10. , Pagnamenta A, Bouckaert Y, Wauthy P, et al. Continuous versus pulsatile pulmonary hemodynamics in canine oleic acid lung injury. Am J Respir Crit Care Med. 2000;162:936-940.
11. Sunagawa K, Yamada A, Senda Y, et al. Estimation of hydromotive source of pressure from ejecting beats of the left ventricle. IEEE Trans Biomed Eng. 1980;27:299-305.
12. Shehata SM, Tibboel D, Sharma HS, et al. Impaired structural remodelling of pulmonary arteries in newborns with congenital diaphragmatic hernia: a histological study of 29 cases. J Pathol. 1999; 189:112-118.
13. Donkier J, Hanet C, Stoleru L, et al. Effect of endothelin-1 at pathologic concentrations on coronary perfusion and mechanical function of normal and postischemic myocardium. J Cardiovasc Pharmacol. 1994;23: 212-219.
14. Yoshimura H, Nishimura J, Sakihara C, et al. Expression and function of endothelins, endothelin receptors, and endothelin converting enzyme in the porcine trachea. Am J Respir Cell Mol Biol. 1997;17:471-480.
15. Berkels R, Bertsch A, Zuther T, et al. Evidence for a NO synthase in porcine platelets which is stimulated during activation/aggregation. Eur J Haematol. 1997;58:307-313.
16. Winer J, Jung CK, Shackel I, et al. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem. 1999;270:41-49.
17. Aguirre JI, Morrell NW, Long L, et al. Vascular remodeling and ET-1 expression in rat strains with different responses to chronic hypoxia. Am J Physiol. 2000;278:L981-L987.
18. Remmelink M, Salmon I, Goldschmidt D, et al. Quantitative measurements of desmin and vimentin immunostains and cell density in leiomyomas and leiomyosarcomas. Anal Cell Pathol. 1996;12:25-44.
19. Winer BJ. Statistical Principles in Experimental Design. 2nd ed. New York: McGraw-Hill; 1971:514-603.
20. Parviz M, Bousamra M II, Chammas JH, et al. Effects of chronic pulmonary overcirculation on pulmonary vasomotor tone. Ann Thorac Surg 1999;67:522-527.
21. Heath D, Edwards JE. The pathology of pulmonary vascular disease: a description of six grades of structural changes in the pulmonary arteries, with special reference to congenital cardiac septal defects. Circulation. 1958;18:533-547.
22. Kafi AS, Mélot C, Vachiéry JL, et al. Partitioning of pulmonary vascular resistance in primary pulmonary hypertension. J Am Cardiol. 1998; 31:1372-1376.
23. Li H, Elton TS, Chen YF, et al. Increased endothelin receptor gene expression in hypoxic rat lung. Am J Physiol. 1994;266:L553-L560.
24. Bauer M, Wilkens H, Langer F, et al. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation. 2002;105:1034-1036.
25. B receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med. 2002;165:398-405.
26. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333:214-221.
27. Black SM, Fineman JR, Steinhorn RH, et al. Increased endothelial NOS in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol. 1998;275:H1643-H1651.
28. Everett AD, Le Cras TD, Xue C, et al. ENOS expression is not altered in pulmonary vascular remodeling due to increased pulmonary blood flow. Am J Physiol. 1998;274:L1058-L1065.
29. Jones PL, Rabinovitch M. Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation. Circ Res. 1996;79:1131-1142.
30. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia: modulation of gene expression by nitric oxide. J Clin Invest. 1995;95:1798-1807.
31. Shehata SM, Mooi WJ, Okazaki T, et al. Enhanced expression of vascular endothelial growth factor in lungs of newborn infants with congenital diaphragmatic hernia and pulmonary hypertension. Thorax. 1999;54: 427-431.
32. Partovian C, Adnot S, Eddahibi S, et al. Heart and lung VEGF mRNA expression in rats with monocrotaline- or hypoxia-induced pulmonary hypertension. Am J Physiol. 1998;275:H1948-H1956.
33. Kasai H, Takanashi M, Takasaki C, et al. Pharmacological properties of endothelin receptor subtypes mediating positive inotropic effects in rabbit heart. Am J Physiol. 1994;266:H2220-H2228.
34. Hill NS, Warburton RR, Pletras L, et al. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. J Appl Physiol. 1997;83:1209-1215.